Genomic Vision and PolyAn ink coverslip production & supply agreement
Date: 2019-10-04   Author: Paroma Bhattacharya  Category: #news

Genomic Vision and PolyAn ink coverslip production & supply agreement

France-based biotechnology company Genomic Vision has reportedly announced a partnership with PolyAn for the manufacture and supply of coverslips. Sources with reliable information reported that the latest development of Genomic Vision’s Life Science Research (LSR) product line has increased the need for high-quality silanized glass coverslips.

Genomic Vision had evidently been looking for a new manufacturing partner to mass produce high-quality coverslips for its LSR line of products.

For the record, Genomic Vision is a Paris-headquartered biotechnology company that develops molecular and AI tools to enhance quality and safety of genetically modified genomes, in particular biomanufacturing and genome editing technologies.

The Company’s proprietary molecular tools apparently deliver accurate quantitative measurements to enable high-confidence characterization of DNA modification in genomes. Currently, these tools are used to monitor DNA replication in cancerous cell for the early detection of cancer and as well as genetic diseases.

Florence Mahé, Head of R&D and manufacturing operations at Genomic Vision, mentioned that PolyAn’s strong surface functionalization, high-quality standard and process scale up capabilities make it the ideal partner for Genomic Vision to manufacture and supply coverslips.

The Genomic Vision coverslip is a key consumable without which DNA could not be properly combined. Coverslip consumption has been steadily growing over the past few years and more than 20,000 units were used worldwide in 2018, Florence added.

PolyAn CEO Fridtjof Lechhart commented that the company is pleased to have set up an exclusive partnership with Genomic Vision and to deliver high-quality surfaces to doctors, pateints and researchers to effectively stretch DNA strands and achieve promising results.

With the growth of various advanced analytical approaches in the LSR field, such as in DNA replication and in Quality Control, the team is assertive to meet the demand and increase the quantity as well as the production,Lechhart stated.  

For the initiated, headquartered in Germany, PolyAn is a nanotechnology firm that specializes to modify surfaces using Molecular Surface Engineering. The company develops and produces consumables for multiplex diagnostic and Life Science Research since 1996.

Genomic Vision had very recently announced that it plans to use molecular combing platforms, FiberVision and FiberComb, designed by the Developmental Therapeutics Branch at the National Cancer Institute (NCI) to study DNA replication in cancerous cells.

Source Credits –

https://www.businesswire.com/news/home/20191002005819/en/Genomic-Vision-PolyAn-Sign-Agreement-Production-Supply



About Author


Paroma Bhattacharya

Paroma Bhattacharya

Paroma currently works as a content developer for AlgosOnline. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched content in diverse fields. Apart from...

Read More

More from Paroma


Post Recommendents

Nomura Holdings to acquire U.S. M&A firm Greentech in US$92m deal
Author: Pankaj Singh

Nomura Holdings, a financial holding company in Japan, has recently announced that it will buy Greentech Capital Advisors, a mergers and acquisitions advisory company from the U.S. that specializes in renewable energy. This will be the company&rsq...


Perfect Day raises $140 Mn in a Series C funding round led by Temasek
Author: Saipriya Iyer

Perfect Day, a US-based food technology startup that has innovated new processes of creating dairy products by using casein, reportedly announced that it raised $140 million in a Series C funding round. This investment...


Current Health raises $11.5 million in Series A funding round
Author: Pankaj Singh

Current Health, a renowned New York based universal patient management platform, reportedly announced that it has closed a $11.5 million Series A funding round which was co-led by UK based MMC Ventures.